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This study describes the disease burden, clinical characteristics, antibiotic management, 
impact of multidrug resistance and outcome of Pseudomonas aeruginosa bloodstream 
infection (PABSI) among children admitted to a tertiary referral hospital for children in Cape 
Town, South Africa.  
 
Methods  
A retrospective descriptive study was conducted at a paediatric referral hospital in Cape 
Town, South Africa. Demographic and clinical details, antibiotic management and patient 
outcome information were extracted from medical and laboratory records. Antibiotic 
susceptibility results of identified organisms were obtained from the National Health 
Laboratory Service database. 
 
Results 
The overall incidence risk of PABSI was 5.4 PABSI episodes / 10,000 hospital admissions and 
the most common presenting feature was respiratory distress, 34/91 (37%). Overall, 69/91 
(76%) of the PA isolates were susceptible to all antipseudomonal antibiotic classes evaluated. 
Fifty (55%) of the PABSI episodes were treated with appropriate empiric antibiotic therapy. 
The mortality rate was 24% and in multivariable analysis, empiric antibiotic therapy to which 
PA isolate was not susceptible to, infections present on admission, and not being in the 




The study provided insight into factors associated with PABSI in a tertiary hospital in Sub-
Saharan Africa. Empiric antipseudomonal antibiotic therapy was associated with a decrease 
in 14-day mortality.  
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Pseudomonas aeruginosa (PA) is a ubiquitous Gram-negative aerobic bacterium usually found 
in water, soil and plants. It grows well at 25°C to 37°C, and its ability to grow at 42°C helps 
distinguish it from many other Pseudomonas species. The features useful for identifying 
Pseudomonas species in the laboratory include a characteristic sweet, grape-like odour during 
culture, the elaboration of a green pigment and production of oxidase (Tang, 2014). It has an 
ability to form biofilm, and this enables it to persist in environmental niches such as the pipes 
and taps in hospitals (Streeter & Katouli, 2016). It is an important opportunistic pathogen in 
humans. Compared to other causes of bloodstream infection (BSI), PA occurs less frequently. 
Studies from South Africa and Ghana have shown that PA causes between 4 and 6.5% of 
Gram-negative BSI (Dramowski et al., 2015; Lochan et al., 2017; Obeng-Nkrumah et al., 2016). 
In some settings PA is more frequently isolated. Recent BSI studies from Finland and the USA 
showed that PA was responsible for 17.9% and 20.2% of all Gram-negative BSI among 
children, respectively (Ivády et al., 2016; Larru et al., 2016).  
 
Pseudomonas aeruginosa typically causes healthcare-associated BSI among children with 
chronic or malignant diseases that are associated with impaired defence mechanisms, and 
among preterm infants due to their immature immune system (Logan et al., 2016; Rosanova 
et al., 2019; Viola et al., 2006). Physical breaches in host defences from surgical incisions and 
insertion of urinary or vascular catheters and endotracheal tubes predispose patients to PA 
bloodstream infection (PABSI) (Streeter & Katouli, 2016). In the intensive care unit (ICU), the 
presence of invasive devices and prolonged use of antibiotics puts patients at risk of PABSI 
(Kim et al., 2014). In HIV-infected children, PABSI is associated with the use of central venous 
catheters and may present as new pulmonary infiltrates and skin lesions (Flores et al., 1993; 
Roilides et al., 1992) and in cystic fibrosis, PA infection is associated with the acceleration of 
lung disease (Burns et al., 2001). Community-acquired PABSI may manifest in children with 
other immunodeficiency states including hypogammaglobulinaemia and neutropaenia (Baro 
et al., 2004; Johnston & Speller, 1977; Sanford et al., 2018). Community-acquired PABSI has 
also been reported among previously healthy, young children without underlying medical 
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conditions (Huang et al., 2002; Kuo et al., 2013). Neutropaenia may be associated with PA 
infections in immunocompetent children as a result of the production and elaboration of PA 
exotoxin A that leads to bone marrow suppression during the acute phase of illness (Huang 
et al., 2002).  
 
The common sources of PABSI in children include the skin and soft tissue, lungs, abdomen 
and catheter-related or it may present without any focus (Rosanova et al., 2019; Yang et al., 
2011). Ecthyma gangrenosum is a characteristic vasculitic skin lesion associated with PABSI. 
It results from perivascular bacterial invasion of the media and adventitia of arteries and veins 
with secondary ischaemic necrosis, inhibition of protein synthesis by PA exotoxin A and 
degradation of elastin by elastase, thus destroying the blood vessel wall support (Kanj & 
Sexton, 2018). The lesions commonly begin as painless red macules which rapidly evolve into 
areas of induration that develop into pustules and/or bullae that may occur anywhere on the 
body but especially on the genitalia, legs, abdomen and extremities. The lesions may become 
haemorrhagic as they evolve and gangrenous cellulitis may occur resulting in sharply 
demarcated, necrotic lesions (Viola et al., 2006). It may aid the clinician in suspecting PABSI 
in children without apparent underlying medical problems or reveal an undiagnosed 
immunodeficiency (Sanford et al., 2018). Recurrent episodes of otitis media may be a 
predisposing factor for PABSI in children with the risk of severe disease enhanced by the 
presence of fever, coagulation abnormalities, pneumonia and neutropaenia (Viola et al., 
2006; Huang et al., 2002; Chuang et al., 2017). Seizures and gastrointestinal findings tend to 
be more common in previously healthy children with PABSI whilst fever and diarrhoea were 
common presenting symptoms in children with community acquired PABSI (Kuo et al., 2013; 
Viola et al., 2006). 
 
The mortality of PABSI is high. In retrospective studies from Argentina and Taiwan, case-
fatality rates of 30% and 35% respectively were documented (Kuo et al., 2013; Rosanova et 
al., 2019). Risk factors for mortality in children with PABSI include septic shock, multidrug-
resistant (MDR) PA isolates, admission to an ICU, the presence of an underlying disease, 
pulmonary source of infection, ineffective empiric antibiotic therapy and diarrhoea as a 
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presenting feature (Akram et al., 2014; Grisaru-Soen et al., 2000 ; Kim et al., 2017; Rosanova 
et al., 2019). Conversely, among adults hospitalised at a tertiary centre in South Korea, Kim et 
al. demonstrated a 22.2% 14-day mortality, with delayed initiation of effective antimicrobial 
therapy for PABSI related to higher mortality (Kim et al., 2014). 
 
PA is intrinsically resistant to certain beta-lactam antibiotics such as ampicillin and ceftriaxone 
and can acquire resistance during therapy to other antibiotics such as the carbapenems 
(Masuda et al., 1999; Okamoto et al., 2001). This makes the selection of empiric antibiotic 
therapy for suspected PABSI challenging. Carbapenems are frequently used empirically for 
serious infections but the growing threat of carbapenem resistance in PA may significantly 
decrease the efficacy of these last-resort antibiotics (Logan et al., 2016). Carbapenem-sparing 
antibiotic regimens such as the combination of piperacillin-tazobactam and amikacin have 
enhanced activity against PA because of the synergistic action of combination antibiotic 
therapy (Drago et al., 2004). In a multinational retrospective study (9 countries, 25 centres) 
involving 767 hospitalised patients with PABSI, treatment with beta-lactam monotherapy 
showed that the use of ceftazidime, an antipseudomonal carbapenem or piperacillin-
tazobactam was not significantly associated with 30-day mortality. No significant differences 
between antipseudomonal antibiotics were demonstrated for clinical failure, microbiological 
failure, or adverse events, however the isolation of PA with new resistance to 
antipseudomonal drugs within 30 days, which was not apparent in the original isolate, was 
significantly more frequent with the use of carbapenems (Babich et al., 2020).  
 
Generally, the major mechanisms of resistance used by PA can be classified as intrinsic, 
acquired and adaptive resistance. Intrinsic resistance of PA includes low outer membrane 
permeability, expression of efflux pumps that expel antibiotics out of the cell and the 
production of antibiotic-inactivating enzymes. Acquired resistance of PA can be achieved by 
either horizontal transfer of resistance genes between organisms or mutational changes 
(Breidenstein et al., 2011). Acquired resistance greatly contributes to the development of 
multidrug-resistant (MDR) strains, which increases the difficulty in eradicating this 
microorganism and leads to more cases of persistent infection and failed antibiotic therapy. 
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Adaptive resistance of PA involves formation of biofilm in the lungs of infected patients where 
the biofilm serves as a diffusion barrier to limit antibiotic access to the bacterial cells 
(Drenkard, 2003). The global burden of resistance among PA isolates is high. Based on the 
drug resistance pattern to antipseudomonal agents, PA can be described as multi-drug 
resistance (MDR), extensively- drug resistant (XDR) or pan-drug resistant (PDR). MDR strains 
are non-susceptible to at least one agent in three or more anti-microbial categories, XDR 
isolates are non-susceptible to at least one agent in all but two or fewer antimicrobial 
categories whilst PDR are non-susceptible to all agents in all antimicrobial categories 
(Magiorakos et al., 2012). The World Health Organization (WHO) has designated carbapenem-
resistant PA as a critical pathogen that requires research and development for new and 
effective antibiotics (WHO, 2017) . Newer beta-lactams such as cefiderocol and imipenem-
cilastatin-relebactam combination therapy have been developed for the treatment of 
infections caused by MDR Gram-negative organisms such as PA, but there is generally less 
clinical experience with them (Kazmierczak et al., 2019; Motsch et al., 2020) . 
 
Few studies have described the prevalence of resistant PA isolates in BSI among children. In 
a study done at a Korean university hospital in 75 children with PABSI, the prevalence of MDR 
PA was 11.3%. In that study, the fatality rate was higher among children with PABSI caused 
by MDR isolates compared to those with non-MDR PA isolates, 57.1% versus 9.1% (Yang et 
al., 2011). At another teaching hospital in Korea, 36.1% of PABSI in children and adolescents 
with febrile neutropaenia was caused by MDR PA strains, and this was associated with a high 
case fatality rate (Kim et al., 2017).  
 
While previous studies from sub-Saharan Africa have reported on the prevalence of PA in 
children with BSI, there are no paediatric studies providing detailed description of PABSI in 
children in sub-Saharan Africa. The present study was undertaken to address this knowledge 
gap. It describes the disease burden, clinical characteristics, antibiotic management, impact 
of multidrug-resistance and outcome of PABSI among children admitted to a tertiary referral 
hospital for children in Cape Town, South Africa. A better understanding of the clinical 
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epidemiology of PABSI in children at our hospital will help guide clinicians in the selection of 
appropriate empiric antibiotics  
 
1.2 Ethical Considerations 
 
The study was submitted for approval to the Departmental Research Committee, Department 
of Paediatrics and Child Health, University of Cape Town; Human Research Ethics Committee 
(HREC), Faculty of Health Sciences, University of Cape Town (Appendix 1); and the Research 
Committee at Red Cross War Memorial Children’s Hospital (Appendix 2). The study was done 
in accordance with the Declaration of Helsinki. The HREC approval number is 107/2018. 
The data was collected retrospectively, thus consent was not obtained from parents/legal 
guardians.  
The data sheets included the names and hospital folder numbers of study subjects which 
enabled the researchers to check information from the hospital folders after data collection 
had been completed. Each name and hospital folder number was linked to a study number. 
Study numbers but not names or hospital folder numbers were entered into an electronic 
database for anonymous analysis and reporting.  
 
Risk to participants 
There were no risks to the patients included in the study. Data was collected retrospectively 
and analysed anonymously.  
 
Benefits to the patient 





1.3 Journal for Publication- International Journal of Infectious Diseases  
 
International Journal of Infectious Diseases (IJID) is a peer-reviewed, open access journal that 
publishes position papers, original clinical and laboratory-based research, together with 
reports of clinical trials, reviews, exceptional case reports. In 2018, the impact factor was 
3.538. The interest areas of the IJID are epidemiology, clinical diagnosis, treatment, and 
control of infectious diseases with emphasis placed on under-resourced countries and this 
motivated my interest in choosing the journal. Original articles do not exceed 3500 words in 
length and the word count is from the introduction through to the end of the 
conclusion/discussion and does not include abstract, tables, figures, acknowledgements or 
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• The incidence risk of Pseudomonas aeruginosa bloodstream infection in our setting was 
low. 
• The majority of Pseudomonas aeruginosa bloodstream infections were healthcare-
associated. 
• 24% of the patients with Pseudomonas aeruginosa bloodstream infections died during 
hospitalisation. 
• Infection present on admission and empiric antibiotics to which Pseudomonas aeruginosa 
isolate was not susceptible to, were associated with 14-day mortality in Pseudomonas 
aeruginosa bloodstream infection. 
• Carbapenem-sparing treatment with antibiotics such as ceftazidime or piperacillin-
tazobactam should be used for Pseudomonas aeruginosa isolates that are susceptible to 

























This study describes the disease burden, clinical characteristics, antibiotic management, 
impact of multidrug resistance and outcome of Pseudomonas aeruginosa bloodstream 
infection (PABSI) among children admitted to a tertiary referral hospital for children in Cape 
Town, South Africa.  
 
Methods  
A retrospective descriptive study was conducted at a paediatric referral hospital in Cape 
Town, South Africa. Demographic and clinical details, antibiotic management and patient 
outcome information were extracted from medical and laboratory records. Antibiotic 
susceptibility results of identified organisms were obtained from the National Health 
Laboratory Service database. 
 
Results 
The overall incidence risk of PABSI was 5.4 PABSI episodes / 10,000 hospital admissions and 
the most common presenting feature was respiratory distress, 34/91 (37%). Overall, 69/91 
(76%) of the PA isolates were susceptible to all antipseudomonal antibiotic classes evaluated. 
Fifty (55%) of the PABSI episodes were treated with appropriate empiric antibiotic therapy. 
The mortality rate was 24% and in multivariable analysis, empiric antibiotic therapy to which 
PA isolate was not susceptible to, infections present on admission, and not being in the 




The study provided insight into factors associated with PABSI in a tertiary hospital in Sub-
Saharan Africa. Empiric antipseudomonal antibiotic therapy was associated with a decrease 
in 14-day mortality.  
 




Pseudomonas aeruginosa (PA) is a ubiquitous Gram-negative bacterium usually found in 
water, soil and plants. It is an important opportunistic pathogen in humans. Compared to 
other causes of bloodstream infection (BSI), PA occurs less frequently. However, studies from 
South Africa and Ghana have shown that PA causes between 4 and 6.5% of Gram-negative 
BSI (Dramowski et al., 2015; Lochan et al., 2017; Obeng-Nkrumah et al., 2016). PA typically 
causes healthcare-associated BSI among children with chronic or malignant diseases that are 
associated with impaired defence mechanisms such as neutropaenia, particularly in intensive 
care settings and among preterm infants with an immature immune system (Logan et al., 
2016; Rosanova et al., 2019; Viola et al., 2006). Community-acquired PA bloodstream 
infection (PABSI) may manifest in children with other immunodeficiency states including 
hypogammaglobulinaemia and neutropaenia (Baro et al., 2004; Johnston & Speller, 1977; 
Sanford et al., 2018). Community-acquired PABSI has also been reported among previously 
healthy, young children without underlying medical conditions (Huang et al., 2002; Kuo et al., 
2013) . 
 
The mortality of PABSI is high. In retrospective studies from Argentina and Taiwan, case-
fatality rates of 30% and 35% respectively were documented (Kuo et al., 2013; Rosanova et 
al., 2019). Risk factors for mortality in children with PABSI include septic shock, multidrug-
resistant (MDR) PA isolates, admission to an intensive care unit (ICU), the presence of an 
underlying disease, a pulmonary source of infection, inappropriate empiric antibiotic therapy 
and diarrhoea as a presenting feature (Akram et al., 2014; Grisaru-Soen et al., 2000; Kim et 
al., 2017; Rosanova et al., 2019).  
 
PA is intrinsically resistant to certain commonly used beta-lactam antibiotics such as ampicillin 
and ceftriaxone and can acquire resistance during therapy to other antibiotics such as the 
carbapenems (Masuda et al., 1999; Okamoto et al., 2001). This makes the selection of empiric 
antibiotic therapy for suspected PABSI challenging. The global burden of resistance among PA 
isolates is high. The World Health Organization (WHO) has designated carbapenem-resistant 
PA as a critical pathogen that requires research and development for new and effective 
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antibiotics (WHO, 2017). Few studies have described the prevalence of resistant PA isolates 
in BSI among children. In a study done at a Korean university hospital in 75 children with 
PABSI, the prevalence of MDR PA was 11.3%. In that study, the fatality rate was higher among 
children with PABSI caused by MDR isolates compared to those with non-MDR PA isolates, 
57.1% versus 9.1%  (Yang et al., 2011). At another teaching hospital in Korea, 36.1% of PABSI 
in children and adolescents with febrile neutropaenia was caused by MDR PA strains, and this 
was associated with a high case-fatality rate of 66.7% (Kim et al., 2017).  
 
While previous studies from sub-Saharan Africa have reported on the prevalence of PA in 
children with BSI, there are no paediatric studies providing detailed description of PABSI in 
children in sub-Saharan Africa. The present study was undertaken to address this knowledge 
gap. It describes the disease burden, clinical characteristics, antibiotic management, impact 
of multidrug resistance and outcome of PABSI among children admitted to a tertiary referral 
hospital for children in Cape Town, South Africa.  
 
METHODS  
Study design, setting and inclusion/exclusion criteria 
This retrospective descriptive study was conducted at Red Cross War Memorial Children’s 
Hospital (RCWMCH), Cape Town, South Africa. This 273-bed facility serves as a referral centre 
for the paediatric population of the Western Cape province as well as surrounding provinces. 
Hospitalised children aged 0 to 14 years with culture- confirmed PABSI that was diagnosed 
between January 2009 and December 2017 were included in the analysis. Repeat blood 
cultures and insufficient information on clinical and antibiotic episodes were excluded.  
 
Data collection 
The Central Data Warehouse (CDW), housed in the information technology department of the 
National Health Laboratory Service (NHLS) in Johannesburg, South Africa, is a database of all 
laboratory investigations performed on patients treated in public sector hospitals and clinics 
in South Africa. The academic and research unit managing the CDW was approached to 
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retrieve the list of children admitted at RCWMCH with laboratory- confirmed PABSI from 
January 2009 until December 2017. This list was used to obtain microbiology results relating 
to every PABSI episode during the study period. These microbiology results were extracted 
from the NHLS microbiology database at Groote Schuur Hospital (GSH), Cape Town. Blood 
culture specimens from children admitted to RCWMCH are routinely transported to the GSH 
microbiology laboratory where they are processed. Clinical data relating to each PABSI 
episode were extracted from the patient hospital records at RCWMCH. Data collected 
included the patient’s demographics, HIV and nutrition status, date of current hospital 
admission and admission in the past 30 days, and clinical information relating to the current 
admission such as clinical diagnosis and antibiotic usage. All microbiology and clinical data 
were entered in study-specific data collection sheets. 
 
Microbiology testing 
All microbiology testing was conducted at the NHLS clinical microbiology laboratory based at 
GSH, which is located 4.3 km from RCWMCH. Blood specimens were collected aseptically from 
patients either from a peripheral venepuncture or a central venous catheter. Blood was then 
inoculated at the bedside into an aerobic paediatric blood culture bottle. From 2009 to 2013, 
the BACTEC 9240 automated blood culture system (Becton Dickinson, Sparks, MD, USA) with 
BACTEC Plus aerobic blood culture bottles was in use. From 2013 until the end of the study 
period, BacT/ALERT PF Plus aerobic paediatric bottles were used along with the BacT/ALERT 
automated blood culture system (bioMerieux Inc., Durham, NC, USA).  
 
At the GSH microbiology laboratory, paediatric blood culture specimens were registered and 
immediately incubated in the automated blood culture instrument. Once the instrument 
flagged positive due to detection by a light emitting diode of carbon dioxide, a Gram stain was 
prepared from the bottle. Bacterial identification and antibiotic susceptibility testing were 
performed according to the results of the Gram stain with final identification by the 
automated Vitek®2 system (bioMérieux, Inc., France) for the duration of the study period.  
Vitek®2ID-GNB and AST-N133 cards were used for identification and susceptibility testing of 
Gram-negative bacilli observed on Gram stain respectively. The AST-N133 card includes the 
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following antibiotics: amikacin, gentamicin, ciprofloxacin, piperacillin-tazobactam, cefepime, 
ceftazidime, tigecycline, meropenem and imipenem. The antibiotic susceptibility testing 
methods and breakpoints are based on the Clinical and Laboratory Standards Institute (CLSI) 
of each year of the study . The breakpoints for meropenem, imipenem and piperacillin-
tazobactam were revised in 2012. Changes in 2012 included an increase in the susceptibility 
breakpoints for piperacillin-tazobactam from ≤64/4 µg/mL to ≤16/4 µg/mL, and the 
introduction of a new intermediate category for piperacillin-tazobactam from 32/4 µg/mL to 
64/4 µg/mL. In addition, the susceptible category breakpoints for imipenem and meropenem 
changed from ≤4 µg/mL to ≤2 µg/mL in 2012, while the intermediate category range changed 
from 8 to 4 µg/mL (CLSI, 2012). Breakpoints for all anti-pseudomonal antibiotics remained the 
same from 2012 until the end of the study period.   
 
Definitions 
BSI was classified as  infection present on admission (IPOA) if PA was cultured from a  blood 
culture specimen obtained on the day of admission to RCWMCH (calendar day 1), 2 days 
before admission or the calendar day after admission (calendar day 2) or healthcare-
associated infection (HAI) if PA was isolated from a blood culture specimen obtained on or 
after the 3rd calendar day of admission to RCWMCH (Centers for Disease Control and 
Prevention (CDC), USA, 2017).  
Date of onset of PABSI: The date on which the positive blood culture for PA was drawn. 
Recurrent bloodstream infection: The re-isolation of PA on blood culture more than 14 days 
after completion of effective antibiotic therapy for the initial or previous PABSI.  
Site of infection: The clinical site of infection as determined by the attending clinician.  
Central venous access device (CVAD): An indwelling venous catheter that was inserted into 
the central venous system with the catheter tip positioned within the superior/inferior vena 
cava or right atrium, such as Hickman, Port-A-Cath, or central venous pressure (CVP) catheters 
(Dougherty, 2007) 
Fever: An axillary temperature greater or equal to 38 degrees Celsius. 
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Anaemia: Blood haemoglobin concentration <11 g/dl (WHO, 2015).  
Antipseudomonal antibiotics included gentamicin and amikacin (aminoglycosides), 
piperacillin (antipseudomonal penicillin), ciprofloxacin (quinolone), ceftazidime and cefepime 
(cephalosporins), meropenem and imipenem (carbapenems), and colistin (polymyxin). 
A PA isolate was classified as (1) multidrug-resistant (MDR) if it was non-susceptible to at least 
one agent in three or more antipseudomonal antibiotic categories, (2) extensively drug-
resistant (XDR) if it was non- susceptible to at least one agent in all but two or fewer 
antipseudomonal antibiotic categories, or (3) pan drug-resistant (PDR) if it was non-
susceptible to all agents in all antipseudomonal antibiotic categories (Magiorakos et al., 
2012).  
Appropriate empiric antibiotic therapy: antibiotic therapy with in vitro activity against the PA 
isolate that was commenced at the onset of bloodstream infection before the antibiogram of 
the isolate was known.  
Definitive antibiotic therapy: antibiotic therapy with in vitro activity against the PA isolate that 
was administered after the antibiogram of the isolate was known. 
HIV status was classified as (1) HIV-infected in a child <18 months of age with a positive HIV 
DNA PCR result confirmed by either a quantitative HIV RNA PCR or repeat HIV DNA PCR on a 
separate sample, or a child ≥18 months of age with 2 positive serological test results (HIV 
ELISA or HIV rapid test) or a positive HIV DNA PCR result confirmed by either a HIV RNA PCR 
or repeat HIV DNA PCR test, (2) HIV-uninfected in a child with a negative HIV serological test 
(HIV ELISA or HIV rapid test) or a negative virological test for HIV (e.g. HIV DNA PCR) or (3) 
Unknown in a child with no history of HIV testing, no record of HIV testing in the NHLS 
laboratory database and whose mother’s HIV status was unknown (Schneider et al., 2008). 
Moderate and severe underweight were defined as weight-for-age Z-score (WAZ) between -2 
and -3 standard deviations (SD) and a WAZ <-3 SD below the median WHO growth reference 
standards, respectively  
Coagulopathy: A prothrombin time of ≥2 seconds, an activated partial thromboplastin time 
of ≥60 seconds or a fibrinogen level of <2 µmol/L (Dellinger et al., 2013).  
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Respiratory failure: the need for mechanical ventilatory support. 
Renal dysfunction: a serum creatinine concentration above the normal age-related range 
(Boer et al., 2010; Pottel et al., 2008).  
Liver dysfunction: a ≥2-fold increase of serum aspartate aminotransferase and/or serum 
alanine aminotransferase concentration and/or a total bilirubin in a child more than 28 days 
old of >70 µmol/L (Dellinger et al., 2013; Goldstein et al., 2005). 
Sample size 
There were no previous studies from Africa to calculate sample size and no similar study. 
However, we estimated a sample size using a retrospective descriptive study from Korea in 
children with Pseudomonas aeruginosa bacteraemia and a prevalence of 2.6% (Zhang et al., 
2012).  The estimated sample size was determined using the formula for a simple prevalence 
study. 
n = z²p (1-p)   
           e²   
Where n= sample size 
z= standard deviation at 95 % (1.96) 
p= prevalence of adherence in children and adolescents  
e= margin of error=5 % (0.05) 
The sample size was calculated as 39. We increased this by 10% to 43 to make up for any 
losses.  
The final estimated sample size was 45. 
 
Statistical analysis 
The data was analysed using STATA Statistical software, release 11, (College Station, Texas, 
USA). Incidence risk of PA-BSI was calculated per 10,000 hospital admissions. Proportions 
were depicted as percentages. Continuous variables were tested for normality and mean and 
standard deviation (SD) or median and interquartile range (IQR) used to describe the data as 
appropriate. The Student’s t- test or Mann Whitney U test were used to compare continuous 
data based on their normal distribution, whilst the chi-squared, and Fisher’s exact test was 
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used to compare categorical data. A two-sided significance level of p<0.05 was considered 
statistically significant. Predictors of 14-day mortality were explored using univariable and 
multivariable logistic regression analyses. The logistic regression model was built by stepwise 
backward selection, incorporating variables which on univariable analysis had a p value <0.20. 
The results of the logistic regression model were expressed as adjusted odds ratio (aOR) and 




During the study period there were 192,547 admissions to RCWMCH and 104 PABSI episodes. 
Analysis of the patient list and microbiology results obtained from the CDW and the NHLS 
clinical microbiology laboratory, GSH, respectively showed that during the study period 104 
PABSI episodes occurred at RCWMCH. These episodes were used to estimate the risk of PABSI. 
Thirteen episodes of PABSI were excluded due to insufficient clinical and antibiotic data, thus 
91 (88%) children were used in the subsequent analyses (Figure 1). 
 
Classification and risk of Pseudomonas aeruginosa BSI 
A total of 104 PABSI episodes was identified among 103 study participants during the study 
period; 69 (66%) episodes were HAIs and 35 (33%) were IPOA. There was one recurrent PABSI 
episode, a HAI which manifested 30 days after the initial PABSI episode. The overall incidence 
risk of PABSI throughout the study period was 5.4 PABSI episodes / 10,000 hospital 
admissions. There was a decline in annual incidence risk from 2009 until 2016 followed by a 
rise in 2017. This increase was mainly related to an increase in the incidence risk of HAI (Figure 








Characteristics of study participants 
Table 1 describes characteristics of 91 PABSI episodes in 91 study participants, 60 (66%) 
episodes were HAIs and 31 (34%) were IPOA. The median time between admission and the 
development of PABSI in the 60 children who developed HAI was 13.5 days (IQR 7.0-28.0). 
The median age was 12 months (IQR 5-59) and 52% of the episodes occurred in females. There 
were 45/91 (50%) children under 1 year, out of which 8/45 ( 18%) were neonates. A higher 
proportion of children with HAI (38/60, 63%), experienced antibiotic exposure during the 12-
month period preceding PABSI compared to children with IPOA (9/31, 29%, p=0.004). There 
were 13 cases of confirmed HIV infection with PABSI, 3/60 (5%) were HAI and 10/31 (32%) 
were IPOA. Fifteen (17%) of the children had underlying chronic illnesses other than HIV 
infection, that was present for at least 6 weeks duration. Eleven children had malignancies, 
namely, acute lymphoblastic leukaemia (3), acute myeloid leukaemia (2), lymphoma (1), 
neuroblastoma (1), craniopharyngioma (1) and germ cell tumour (1). Other chronic diseases 
included chronic lung disease (2), Fanconi anaemia (1) and aplastic anaemia (1). Children with 
IPOA had a significantly higher frequency of chronic diseases other than HIV, compared to 
those with HAI, (9/31, 29%) and (6/60, 10%) respectively, p=0.034. 
Presenting features and complications of PABSI 
Respiratory distress was the commonest presenting feature overall (34/91, 37%) and for HAIs 
(23/60, 38%) whereas diarrhoea was the commonest presenting feature for IPOA (13/31, 
42%). Shock as a presenting feature was significantly more frequent among children with 
IPOA (9/31, 29%) than HAI (4/60, 7%), p = 0.009. Pneumonia was the most frequent site of 
infection, occurring in 33/91 (36%) of the PABSI episodes (Table 2).  
Shock, as determined by the attending clinicians, was the commonest complication, occurring 
in 16/91 (18%) of the children; 11/16 (69%) required inotropic infusions. Shock, liver 
dysfunction and 14-day mortality were significantly more frequent complications in children 






Susceptibility profile of PA isolates and antibiotic therapy 
Figure 2 summarises the susceptibility profile of the PA isolates during the study period. 
Overall, 69/91 (76%) of the PA isolates were susceptible to all antipseudomonal antibiotic 
categories evaluated, 12/91 (13%) isolates were MDR, 8/91 (9%) isolates were XDR and 2 (2%) 
isolates were PDR. The proportion of HAI isolates amongst the resistant isolates was 8/12 
(67%) MDR, 7/8 (88%) XDR, and all the PDR isolates.  
There were 19/91 (21%) isolates that were resistant to both imipenem and meropenem; 
there were an additional 2 that were resistant only to imipenem but not to meropenem i.e. a 
total of 21/91 (23%) isolates were resistant to imipenem. Ten meropenem-resistant isolates 
were susceptible to ceftazidime, (10/91; 9%), while 4/91 (4%) ceftazidime-resistant isolates 
were susceptible to meropenem. There were 8/91 (9%) isolates that were resistant to both 
ceftazidime and meropenem. Furthermore, of the 20/91 (22%) isolates resistant to 
gentamicin, 9/20 (45%) were susceptible to amikacin.  
 
Fifty (55%) of the PABSI episodes were treated with appropriate empiric antibiotic therapy. A 
higher proportion of HAI PABSI episodes received appropriate empiric antibiotic therapy 
compared to IPOA PABSI episodes; 37/60 (62%) versus 13/31 (42%). This difference was, 
however, non-significant, p=0.081. Three antibiotics frequently used in empiric therapy for 
both HAI and IPOA were meropenem 27/91(30%), piperacillin-tazobactam 19/91(21%), 
amikacin 18/91 (20%). Piperacillin-tazobactam was frequently combined with amikacin for 
empiric therapy 18/19 (95%). There were 7/31 (23%) IPOA episodes that were treated with 
empiric cephalosporins therapy; 5/7 (71%) received ceftriaxone and 2/7 (29%) cefotaxime. 
Six (19%) of the IPOA episodes received ampicillin monotherapy as empiric antibiotic therapy 
and in a further 5/31 (16%) episodes, ampicillin in combination with gentamicin, to which 
none of the isolates were susceptible. There were 3/31 (10%) IPOA episodes that were treated 
with empiric piperacillin-tazobactam plus amikacin, but the isolates were resistant to both 
antibiotics. In 23/60 (38%) episodes of HAI that received  empiric antibiotic to which PA isolate 
was not susceptible to, 8/23 (35%) received ertapenem which is not an antipseudomonal 
antibiotic, 9/23 (39%) received piperacillin-tazobactam and amikacin and 6/23 (26%) received 
meropenem, to which the isolates were resistant. 
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The mean time ± SD to effective antibiotic therapy (appropriate empiric antibiotic therapy or 
definitive antibiotic therapy) was 1.3 days ± 1.1. The difference in mean time to effective 
antibiotic therapy for HAI was 1.2 days ± 0.9 and 1.6 days ± 1.5 in IPOA, this was not significant 
(p = 0.112). The antibiotic most frequently used as definitive antibiotic therapy for both IPOA 
and HAI was meropenem. Overall, 37/91 (41%) PABSI episodes were treated with 
meropenem; 23 of these 37 episodes (62%) isolates were caused by isolates that were 
susceptible to ceftazidime. By contrast, only 18% of the PABSI episodes were treated with 
ceftazidime (Table 4). 
 
Outcome  
There were 69/91 (76%) PABSI episodes that were successfully treated, with the children 
being discharged from hospital after these episodes. Twenty-two (24%) of the children died 
during their hospitalisation. Most of the deaths, 17/22 (77%), occurred within 14 days of 
hospitalisation as a direct result of PABSI. The median time (IQR) to death of these 17 children 
was 1.4 (1.0–8.3) days and 11/17 (65%) of these deaths were due to IPOA. Of the 5 deaths 
that occurred after 14 days, the median time (IQR) to death was 22.5 (20.8-30.3) days and 3/5 
(60%) had IPOA. 
 
On multivariable analysis, empiric antibiotic therapy to which PA isolate was not susceptible 
to, IPOA, and not being admitted in the ICU at the time that PABSI was diagnosed were 
significantly associated with 14-day mortality. Multidrug-resistant, XDR or PDR isolates were 











This retrospective descriptive study was conducted on laboratory confirmed PABSI in children 
admitted to RCWMCH between 1 January 2009 and 31 December 2017. To the best of our 
knowledge, this is the first study from sub-Saharan Africa describing PABSI in detail among 
hospitalised children. The majority of the PABSI episodes, 69/104(66%) were HAIs. This is 
consistent with previous research that showed that PA infections are mostly healthcare-
associated (Rosanova et al., 2019; Yang et al., 2011). Environmental analysis suggests that PA 
is found in the moist areas of hospitals such as sinks and colonises respiratory equipment in 
Intensive Care Units ( ICUs) (Grisaru-Soen et al., 2000), highlighting the importance of good 
infection prevention and control practices in preventing healthcare-associated PABSI.  
 
In addition to hospital admission, host factors are important determinants of infection. The 
prevalence of underlying chronic diseases and HIV infection were significantly higher in 
children with IPOA in this study. In these children, impaired host defence mechanisms are 
likely to increase the risk of PABSI as described in previous studies (Kim et al., 2017; Zhang et 
al., 2012). The CDC definition for IPOA used in the present study includes all infections in 
whom the corresponding isolates were cultured on the day of admission, 2 days before 
admission or the day after admission, irrespective of a recent hospitalisation. In the present 
study 20/31 (65%) of the PABSI episodes classified as IPOA were preceded by hospitalisation 
occurring within 28 days prior to the current hospitalization, suggesting that the hospital 
environment may have predisposed some of these children to PA colonisation, and effective 
IPC practices may have prevented some of these PABSI episodes.  
 
PABSI can present with common childhood symptoms of a febrile illness such as respiratory 
distress, diarrhoea and discharging ears or with severe manifestations such as septic shock 
(Viola et al., 2006; Zhang et al., 2012). In this study, respiratory distress and diarrhoea were 




Healthcare-associated infections were significantly more frequent in children who developed 
PABSI in the ICU, those with a central venous catheter and/or endotracheal tube, and those 
who had had surgery during the current admission. Patients treated in the ICU tend to be 
immunocompromised, require invasive procedures and may be exposed to broad-spectrum 
antibiotics, and in this study those who had received intravenous broad-spectrum antibiotics 
such as piperacillin-tazobactam or meropenem 12 months prior to the current admission had 
significantly more HAI than IPOA. Implementation of appropriate infection prevention and 
control intervention bundles and antimicrobial stewardship must be part of ICU management 
to decrease the incidence of HAI caused by PA. 
 
The overall in-hospital mortality rate of 24% was lower than reported in previous paediatric 
studies. At a single centre in China, the overall mortality rate was 52% over a 5-year period 
among 36 children, with a significant association between mortality and ineffective initial 
antibiotic therapy (Zhang et al., 2012). In Buenos Aires, a high overall mortality of 31% was 
reported among 100 children over a 3-year period. The deaths were associated with 
admission to ICU, primary bacteraemia or multidrug-resistant isolates (Rosanova et al., 2019). 
The lower mortality in our study is likely to have been the result of the majority, 50/91(55%), 
of BSI events receiving appropriate empiric antibiotic therapy, as confirmed in the analysis of 
the determinants of 14-day mortality. In other studies, MDR PA and carbapenem resistance 
were found to be associated with mortality (Lee et al., 2017), but this was not demonstrated 
in our study.  
 
At RCWMCH, the combination of piperacillin-tazobactam and amikacin is frequently used 
empirically when HAI is suspected. However, a carbapenem antibiotic, usually meropenem is 
frequently used with or without vancomycin as empiric antibiotic therapy in children with 
severe HAI including when septic shock is present. Of the HAI and IPOA isolates, 83% and 90% 
respectively, were susceptible to amikacin, whereas 58% and 61% of the HAI and IPOA isolates 
respectively, were susceptible to piperacillin-tazobactam. Thus, most PA isolates were 
susceptible to at least one antibiotic in this empiric combination. 
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Of 19 isolates that were resistant to meropenem, 10 remained susceptible to ceftazidime, an 
effective antipseudomonal antibiotic. This implies that ceftazidime can be prescribed in a 
subset of carbapenem-resistant PA infections, as a colistin-sparing intervention. Furthermore, 
the polymyxins have a narrow therapeutic window, and the major adverse effects of 
neurotoxicity and nephrotoxicity, makes the use of alternative agents such as ceftazidime 




Due to the retrospective study design, there were limitations in the availability and 
completeness of clinical and laboratory data. Additionally, information on previous 
antimicrobial exposure was limited to what was documented in the patient hospital records. 
Our sample size was small and was probably underpowered to explore risk factors associated 
with 14-day mortality comprehensively. Furthermore, our study did not include an 
appropriate control group, hence risk factors for PABSI were not evaluated. Despite these 






The study provides useful insights about PABSI at our institution. The most common 
presenting symptom was respiratory distress, whilst independent determinants of 14-day 
mortality were empiric antibiotic therapy to which PA isolate was not susceptible to, and 
infections present on admission to hospital. Further research is required to determine 
whether the presentation of PABSI, PABSI-associated mortality and the determinants of PABSI 
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Figure 1. Selection of Pseudomonas aeruginosa bloodstream infection episodes for data analysis. 
CDW, Central Data warehouse; PABSI, Pseudomonas aeruginosa bloodstream infection; RCWMCH, 
Red Cross War Memorial Children’s Hospital. 
 
146 positive blood culture results 
for Pseudomonas aeruginosa were 
identified by the CDW among 
children hospitalised at the 
RCWMCH from 1 January 2009 to 
31 December 2017 
 Exclusions: 
36 (24.7%) repeat blood culture 
results 
4 (2.7%) post-mortem culture results 
in the absence of an infection 
1 (0.7%) vitreous culture result 




104 PABSI episodes were used to 
calculate incidence risk  
 
Exclusion of 13 (12.5 %) PABSI 
episodes because of insufficient 
antibiotic and/or clinical 
information  
91 (87.5%) PABSI episodes used in 







Figure 2. Annual incidence risk per 10 000 hospital admissions. HAI, healthcare-associated infection; 


















































Figure 3. Annual antibiotic susceptibility profile of Pseudomonas aeruginosa isolates by antipseudomonal 
antibiotic susceptibility category, 2009-2017. Multidrug-resistant (MDR), non-susceptible to at least one agent 
in three or more antipseudomonal antibiotic categories; extensively drug-resistant (XDR), non-susceptible to at 
least one agent in all but two or fewer antipseudomonal antibiotic categories; pan drug-resistant (PDR), non-


























































































Age (months) median (IQR)             12 (5-59) 10 (4.5-46) 19 (6-69) 0.065 
Age category, n/N (%)     
      <1 year 45 (50) 34 (57) 11 (36) 0.107 
      1-5 years 22 (24) 11 (18) 11 (36)  
      >5 years 24 (26) 15 (25)  9 (29)  
Gender, n/N (%)     
      Male 44 (48) 27 (45) 17 (56) 0.387 
      Female 47 (52) 33 (55) 14 (45)  
HIV status, n/N (%)     
      HIV-infected 13 (14) 3 (5) 10 (32)  0.002 
      HIV-uninfected 51 (56) 36 (60) 15 (48)  
      Unknown 27 (30) 21 (35) 6 (19)  
Weight-for-age, Z score category, n/N (%)     
       Moderate underweight 9 (10) 3 (5) 6 (20) 0.008 
       Severe underweight 22 (25) 11 (19) 11 (37)  
Temperature in degrees Celsius      
       <35⁰C 3 (3) 1 (2) 2 (7) 0.459 
       >35.5-37.9⁰C 19 (22) 12 (21) 7 (23)  
       ≥38.0⁰C 65 (75) 44 (77) 21 (70)  
Anaemia  64 (70) 40 (67) 24 (77) 0.210 
Hospitalisation in the 28-day period preceding the 
current admission, n/N (%)  
47 (52) 27 (45) 20 (65) 0.121 
Exposure to selective intravenous antibiotics, in 
the preceding 12 months, n/N (%) 
47 (52) 38 (63) 9 (29) 0.004 
 
Selective intravenous antibiotics exposure in the 
preceding 12 months, n/N (%) 
    
          Gentamicin or amikacin 23 (25) 19 (32) 4 (12) 0.074 
          2nd to 4th generation cephalosporins 
 
13 (14) 8 (62) 5 (39) 0.757 
         Piperacillin-tazobactam 12 (13) 12 (20) 0 (0) 0.005 
         Meropenem or ertapenem 16 (18) 15 (25) 1 (3) 0.009 
Chronic diseases other than HIV infection, n/N (%) 15 (17) 6 (10) 9 (29) 0.034 
Any ICU admission in this hospitalisation, n/N (%) 61 (67) 50 (83) 11 (35) 0.0001 
Central venous access device in situ, n/N (%) 59 (55) 48 (80) 11 (36) 0.0001 
Endotracheal Intubation in situ, n/N (%) 54 (60) 46 (77) 8 (26) 0.0001 
Burn wound, n/N (%) 19 (21) 11 (18) 8 (27) 0.416 
 Surgery during current admission, n/N (%) 46 (51) 39 (65) 7 (23) 0.0001 
 
*Comparison of HAI and IPOA, HAI, healthcare-associated infection; IPOA, infections present on admission; PABSI, Pseudomonas 
aeruginosa bloodstream infection; C, Celsius; ICU, intensive care unit  
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Presenting featuresa     
      Respiratory distress 34 (37) 23 (38) 11 (36) 0.487 
      Diarrhoea 29 (32) 16 (27) 13 (42) 0.107 
      Wound infection 23 (25) 18 (30) 5 (16) 0.116 
      Shock 13 (14) 4 (7) 9 (29) 0.009 
      Ecthyma gangrenosum 3 (3) 1 (2) 2 (7) 0.267 
      Otitis media 4 (4) 1 (2) 3 (10) 0.113 
      Otherb 7 (8) 3 (5) 4 (13) 0.224 
Site of infection     
        No definable focus 18 (20) 12 (20) 6 (19) 1.000 
        Pneumonia 33 (36) 22 (37) 11 (36) 1.000 
        Gastrointestinal tractc 7 (8) 3 (5) 4 (13) 0.224 
        Skin & soft tissue infection 20 (22) 16 (27) 4 (13) 0.184 
        Line infection 8 (9) 6 (10) 2 (7) 0.711 
 
        Urosepsis 4 (4) 1 (2) 3 (10) 0.132 
 
HAI, healthcare-associated infection; IPOA, infection present on admission; a, some patients 
presented with > 1 presenting feature; b, vomiting (2), renal angle tenderness (1), necrotising bowel 
(1), tachycardia (1), eye discharge (1), acute abdomen (1); c, gastroenteritis (4), acute appendicitis 


























Shock 16 (18) 7 (12) 9 (29) 0.047 
Coagulopathy 10 (11) 5 (8) 5 (16) 0.300 
Renal dysfunction 12 (13) 7 (12) 5 (16) 0.534 
Liver dysfunction 4 (4) 0 (0) 4 (13) 0.012 
Respiratory failure 11 (12) 6 (10) 5 (16) 0.500 
14-day mortality 17 (19) 6 (10) 11 (36) 0.005 
 
HAI, healthcare-associated infection; IPOA, infection present on admission 
 
 




















Table 4. Antibiotic susceptibility of Pseudomonas aeruginosa bloodstream infection isolates, and the 
definitive antibiotic therapy used during the study period 
Antibiotic Susceptibility of PA isolates to anti-
pseudomonal antibiotics  
Antibiotics used as definitive antibiotic 
therapy 








n/N (%)                    
HAI  




 n/N (%) 
Total  
 N= 91 
 n/N (%) 
Gentamicin 43 (72) 28 (90) 71 (78) 5 (8) 2 (7) 7 (8) 
Amikacin 50 (83) 28 (90) 78 (86) 10 (17) 6 (19) 16 (18) 
Ciprofloxacin 42 (70) 28 (90) 70 (77) 12 (20) 7 (23) 19 (21) 
Piperacillin-
tazobactam 
35 (58) 19 (61) 54 (59) 12 (20) 9 (29) 21 (23) 
Ceftazidime 50 (83) 29 (94) 79 (87) 8 (13) 8 (26) 16 (18) 
Cefepime 47 (78) 26 (84) 73 (80) 11 (18) 2 (7) 13 (14) 

































Table 5.  Predictors of 14-day mortality in children with Pseudomonas aeruginosa bloodstream infection  
Variable Unadjusted OR (95% 
confidence interval) 
P-value Adjusted OR (95% confidence 
interval) 
P value 
Age category N=91     
    < 1 year  n=  45 1                _  
    ≥ 1 year n= 46 0.66 (0.23-1.93) 0.45   
 
Weight N=88     
     Normal weight n=57 1    
    Moderate or severe 
    Underweight n=31 
0.44 (0.15-1.32) 0.10 1.60 (0.330-7.803) 0.557 
 
 
Admission in a health care 
facility 28 days prior to current 
hospitalisation N= 34 
 
0.80 (0.27- 2.4) 0.79                   _ 
 
 
Chronic disease (excluding HIV) 
N=80  
1.2 (0.24-6.13) 0.827 
 
 
                  _  
HIV status  N= 91     
     HIV-uninfected n= 51 1    
     HIV-infected n= 13 1.34 (0.32- 5.68) 0.70                  _  
     HIV status unknown n= 27 0.89 (0.22-3.62) 0.87 
 
  
Nature of infection N=91     
    IPOA n= 31 1    
    HAI n= 60 0.202 (0.066-0.619) 0.005 0.083 (0.01-0.60) 0.013 
 
MDR, XDR or PDR isolates 
 N=22 
1.05 (0.30-3.61) 0.945                _  
Appropriate empiric antibiotic 
N = 50 
0.19 (0.06-0.63) 0.007 0.23 (0.07-0.82) 0.023 
     
Burn wounds N=19 2.24 (0.47-10.77) 0.315        _ 
 
 
Septic shock (as a presenting 
feature or complication of 
PABSI) N=29 




1.47 (0.43-4.99) 0.540 -  
Surgery during current 
admission N=46 
 
1.96 (0.64-6.0) 0.235 -  
ICU management N=30     
    Patient diagnosed with PABSI           
   whilst in the ICU n= 11 
0.43 (0.15-1.25) 0.101 0.04 (0.005-0.365) 0.004 
    Patient requiring ICU 
    care after PABSI  
    diagnosis n=19 
1.21 (0.399-3.670) 0.737 -  
OR, odds ratio; HAI, healthcare-associated infection; IPOA, infection present on admission; MDR, multi-drug resistant; XDR, 
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Symbols for units of measurement must accord with the Système International (SI)  
However, blood pressure should be expressed in mmHg and haemoglobin as g/dl. 
GenBank/DNA sequence linking  
Many Elsevier journals cite "gene accession numbers" in their running text and footnotes. Gene accession numbers refer to genes or DNA 
sequences about which further information can be found in the databases at the National Center for Biotechnical Information (NCBI) at 
the National Library of Medicine. Elsevier authors wishing to enable other scientists to use the accession numbers cited in their papers via 
links to these sources, should type this information in the following manner: 
For each and every accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the 
accession number should always be capitalised. (See example below). This combination of letters and format will enable Elsevier's 
typesetters to recognise the relevant texts as accession numbers and add the required link to GenBank's sequences. 
Example: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228), a B-cell tumor from a chronic lymphatic leukemia 
(GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)". 
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link. In the 
final version of the printed article, the accession number text will not appear bold or underlined. In the final version of the electronic 
copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that 
source from the article. 
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Electronic artwork  
General points 
• Make sure you use uniform lettering and sizing of your original artwork.  
• Embed the used fonts if the application provides that option.  
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.  
• Number the illustrations according to their sequence in the text.  
• Use a logical naming convention for your artwork files.  
• Provide captions to illustrations separately.  
• Size the illustrations close to the desired dimensions of the published version.  
• Submit each illustration as a separate file. 
• Ensure that color images are accessible to all, including those with impaired color vision. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native 
document format.  
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the 
images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations 
given below):  
EPS (or PDF): Vector drawings, embed all used fonts.  
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.  
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.  
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi. 
Please do not:  
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of 
colors;  
• Supply files that are too low in resolution;  
• Submit graphics that are disproportionately large for the content. 
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct 
resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that 
these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced 
in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after 
receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation 
of electronic artwork. 
Figure captions  
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title 
(not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols 
and abbreviations used. 
Tables  
 
Each table must be presented at the end of the manuscript on a separate page and numbered in order of appearance in the text. The title 
of the table must appear after the number. Each table must include appropriate headings. Footnotes, when necessary, must be identified 
by letters. Units of measurement must be clearly indicated. A table can include references if appropriate. 
References  
Citation in text  
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the 
abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be 
mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal 
and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a 
reference as 'in press' implies that the item has been accepted for publication. 
Web references  
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, 
author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the 
reference list) under a different heading if desired, or can be included in the reference list. 
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Data references  
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data 
reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, 
version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly 
identify it as a data reference. The [dataset] identifier will not appear in your published article. 
Reference management software  
Most Elsevier journals have their reference template available in many of the most popular reference management software products. 
These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, 
authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be 
automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample 
references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes 
before submitting the electronic manuscript. More information on how to remove field codes from different reference management 
software. 
 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link: 
http://open.mendeley.com/use-citation-style/international-journal-of-infectious-diseases 
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice. 
Reference style  
Text: All citations in the text should refer to:  
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;  
2. Two authors: both authors' names and the year of publication;  
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.  
Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or 
vice versa.  
Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999)…. Or, as demonstrated (Jones, 1999; Allan, 2000)… Kramer 
et al. (2010) have recently shown …' 
List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from 
the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.  
Examples:  
Reference to a journal publication:  
Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2010;163:51–9. 
https://doi.org/10.1016/j.Sc.2010.00372.  
Reference to a journal publication with an article number:  
Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon. 2018;19:e00205. 
https://doi.org/10.1016/j.heliyon.2018.e00205. 
Reference to a book:  
Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.  
Reference to a chapter in an edited book:  
Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic 
age. New York: E-Publishing Inc; 2009. p. 281–304. 
Reference to a website: 
Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/, 
2003 (accessed 13 March 2003). 
Reference to a dataset: 
[dataset] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, 
Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1. 
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by "et al." For 
further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 
1997;277:927–34) (see also Samples of Formatted References). 
Video  
 
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or 
animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. 
This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it 
should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure 
that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred 
maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your 
article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or 
animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For 
more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print 
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version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this 
content. 
Supplementary material  
 
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted 
supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your 
material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to 
supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on 
a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version. 
 
Online proof correction  
 
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. 
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs 
online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions 
from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, 
eliminating the potential introduction of errors. 
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-
mail we send to authors, including alternative methods to the online version and PDF. 
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, 
editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only 
be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one 
communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is 
solely your responsibility. 
Offprints  
 
The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is 
in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via 
the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at 
any time via Elsevier's Author Services. 
 
 
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to 
get in touch. 












5: DATA COLLECTION SHEET 
 
Biographical Information 
Study No  
Folder No  
Date of Birth  
Gender Male Female 
Admission mass (kg)  WAZ score 
Admission height/length(cm)  WHZ score 
Nutritional status (Z score)  
Presence of oedema Yes                                            No 
 
ADMISSIONS 
Admission Status at RXH 
Date of current 
admission to 
RXH 
 Time of admission 
to RXH: 
Ward / dept in which Blood culture 
was taken: 
Admission to 
RXH in past 28 
days 
Yes/No Duration  
No of admissions to RXH 
in past 1 year 
Date of Admission Duration of admission 
1.    
2.    
   
   
Admission to ICU in past 
28 days 
            Yes /No               Duration of admission 
   
Admissions to ICU in 
past 1 year 
Date of admission Duration of admission 
   
   
 
Admission to other health care facilities 













Patient tested for HIV Yes No Unknown 
HIV Test Rapid PCR Elisa 
Date test done    
HIV exposed Yes  No Unknown 
HIV infected Yes No Unknown 
 Date Values  
CD4 %/Abs(baseline) (µL)    






Viral load (most 
recent)/(copies/ml) 
  
Treatment with ART at 
time of blood culture 
Yes  No Unknown 
Date of ART initiation  Duration on ART  
 
Clinical features at time of bloodstream infection 
Symptoms/Signs Yes No  
Diarrhoea    
Shock Hypovolemia Cardiogenic Septic 
Ecthyma gangrenosum    
Otitis media    
Seizures    
Wound sepsis    
Respiratory distress    
Hypoxia (sats < 90⁰C    
Other    
 
Identified focus of infection at time of bloodstream infection?         Yes                   No 
Focus of infection Indicate as 
appropriate 




Septic Arthritis  
Catheter related blood stream 
infection 
 
Soft tissue infection  
Otitis media  
60 
 
Urinary tract infection  
Other  
 
Temperature at time of blood stream infection /⁰C………………………………………. 
Evidence supporting an invasive infection at time of bloodstream infection 
Clinical diagnosis of infection Yes  No  
Fever≥ 38⁰   
Elevated white cell count   
Low white cell count   
Elevated C reactive protein   
Procalcitonin   
Other (specify)   
 
Underlying medical illness or risk factors 
Medical illness /Risk 
factors 
Yes No Other information if indicated 
Chronic lung disease    
Cystic fibrosis    
HIV    
Burns    
Malnutrition    
Malignancy specify type    
Immunosuppressive 
therapy 
   
Steroid therapy (> 1 month 
duration) 
   
Permanent indwelling 
catheter specify type 
   
Intraosseous assess    
Central lines- 
CVP/Broviac/Hickman 
   
Peripheral venous catheter    
Surgical drains    
Intravenous fluid 
administration 
   
Naso/tracheal intubation    
Tracheostomy    
Urinary catheter    
Surgery during admission    





Investigations at time or close to bloodstream infection  
Investigation  Date/Time Value 
Haemoglobin (g/dl)   
MCV (fl)   
White cell count (x 109 cells/L)    
Neutrophil count (x 109 cells/L)   
Band count   
Lymphocyte count (x 109cells/L)   
Platelet count (x 109 cells/L)   
C reactive count(mg/dL)   
Procalcitonin(µg/dL)   
Other relevant results   
   
 
DIAGNOSIS 
Diagnosis during current admission 
Initial diagnosis  
Additional diagnoses  
Final diagnosis  
 
Pseudomonas Aeruginosa Bloodstream Infection Diagnosis 
Date blood culture was taken  
Time blood culture taken if available  
Date blood culture was received  
Time blood culture was received if available  
 
 
History of recurrent blood stream infection 
Yes No 
Date(s) of the other episode  
Time between episodes  
 
 
Other Positive culture specimen 
Site Date Organism(s) Sensitivity Resistance 
     






Antibiotic Sensitivity Profile to Pseudomonas Aeruginosa  
Antibiotic Sensitive Resistant 
Amikacin   
Tobramcyin   
Gentamicin   
Ceftazidime   
Cefepime   
Ciprofloxacin   
Levofloxacin   
Piperacillin    
Piperacillin/tazobactam   
Ticarcillin/clavulanate   
Imipenem   
Meropenem   
Other   
 
 
Antibiotic exposure in the last year 
Antibiotic exposure  Yes  No Name of drug Duration of 
exposure 
Carbapenems     
4th generation cephalosporin     
Fluoroquinolones     
Aminoglycosides     
Piperacillin- tazobactam     
Ticarcillin-clavulanic acid     
     
 
 
Empiric Antibiotic at time of/ prior to blood culture taken  
Name of 
Antibiotic 
Date and time of 
start 
Date and time ended Duration Route 
     
     







Empiric Antibiotic after blood culture taken if applicable 
Name of 
Antibiotic 
Date and time 
started 
Date and time ended Duration Route 
     
     
     
 
Definitive Antibiotics in response to blood stream infection 
Antibiotic Name Date of start Date ended Duration Route 
      
      
 
 
Complications and outcome 
Complications 
Complications Yes No 
Septic shock/ Inotropic 
Support 
  
DIC   
Renal failure   
Liver dysfunction   
Respiratory Failure   








ICU admission (if applicable) 
Date of admission Total duration of 
admission 
Reason for admission Outcome 
    
 
Hospital outcome 
Discharge Yes No 





Death Yes No 
Date of death  Time of death  
Cause of death  
 
